CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 16 enrolled
Drug / intervention
Fibersym +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04820322
NCT04820322N/ACompleted
CompareCT.gov

Comparison of Postprandial Glycemic and Insulinemic Response to a Cookie With or Without Added Fibersym After Three Days of Pre-feeding: An Acute Double-blind, Randomized Controlled Clinical Trial

MGP Ingredients, Inc.·interventional·Posted Mar 29, 2021·Updated Jan 22, 2025

In Brief

A clinical study evaluating Fibersym and Control cookie for Postprandial Hyperglycemia. Completed, enrolled 16 participants across 1 site.

Detailed Summary

Fibersym® is a RS4-type resistant modified wheat starch in which over 85% of the total starch is resistant starch as measured by AOAC method 991.43. It is meant to be consumed on a regular basis and doses up to 33g/day can be tolerated. The effect of a Fibersym-containing meal on postprandial glucose and insulin levels when compared to a control meal, where both meals contain the same amount of available carbohydrate, is not known. This study therefore investigated the acute effect of a Fibersym cookie and a control cookie matched for available carbohydrate after a 3-day habituation period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostprandial Hyperglycemia
CountriesCanada
CollaboratorsGlycemic Index Laboratories, Inc

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedMar 29, 2021
Enrollment StartAug 24, 2018
Primary CompletionOct 19, 2018
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.3 years ago

Interventions

Fibersymother

RS4-type resistant modified wheat starch

Control cookieother

control cookie